The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma

Cancer Biology and Therapy

Volumn 12, Issue 12, 2011, Pages 1019-1022

  Abraham, Ronnie M ^a   Zhang, Qian ^a   Odum, Niels ^b   Wasik, Mariusz A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CTCL; FoxP3; IL 10; IL 2; PD L1; STAT3; STAT5; Th17; Treg

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

CANCER IMMUNOLOGY; CELL SURFACE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; MOLECULAR CLONING; PHENOTYPE; PHENOTYPIC PLASTICITY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84055184933     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.12.18144     Document Type: Review

References (41)

1. Dummer R. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006; 33:S33-6; PMID:16516674; http://dx.doi.org/ 10.1053/j.seminoncol.2005.12.021
2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-85; PMID:15692063; http://dx.doi.org/10.1182/blood-2004-09-3502
3. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005; 54:1153-61; PMID: 15868167; http://dx.doi.org/10.1007/s00262-005-0699-9
4. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801-5; PMID:15286781; http://dx.doi.org/10.1038/ nm0804-801
5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64; PMID:7636184
6. Tran DQ, Ramsey H, Shevach EM. Induction of FoxP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983-90; PMID: 17644734; http://dx.doi.org/10.1182/blood-2007-06- 094656
7. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-307; PMID:17922010; http://dx.doi.org/10.1038/ nm1652
8. Soper DM, Kasprowicz DJ, Ziegler SF. IL-2Rbeta links IL-2R signaling with FoxP3 expression. Eur J Immunol 2007; 37:1817-26; PMID:17559173; http://dx.doi.org/10.1002/eji.200737101
9. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al. FoxP3 controls regulatory T-cell function by interacting with AML1/ Runx1. Nature 2007; 446:685-9; PMID:17377532; http://dx.doi.org/10.1038/nature05673
10. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126:375-87; PMID:16873067; http://dx.doi.org/10.1016/j.cell.2006.05.042
11. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FoxP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103:6659-64; PMID: 16617117; http://dx.doi.org/10.1073/pnas.0509484103
12. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Sakaguchi S. Homeostatic maintenance of natural FoxP3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201:723-35; PMID:15753206; http://dx.doi.org/10.1084/jem.20041982
13. Williams LM, Rudensky AY. Maintenance of the FoxP3-dependent developmental program in mature regulatory T cells requires continued expression of FoxP3. Nat Immunol 2007; 8:277-84; PMID: 17220892; http://dx.doi.org/10. 1038/ni1437
14. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated FoxP3 expression. Nature 2007; 445:766-70; PMID:17220876; http://dx.doi.org/10.1038/nature05479
15. Wildin RS, Freitas A. IPEX and FoxP3: clinical and research perspectives. J Autoimmun 2005; 25(Suppl): 56-62; PMID:16243487; http://dx.doi.org/10.1016/j. jaut.2005.04.008
16. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome (IPEX) is caused by mutations of FoxP3. Nat Genet 2001; 27:20-1; PMID:11137993; http://dx.doi.org/10.1038/83713
17. Randolph DA, Fathman CG. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006; 57:381-402; PMID:16409156; http://dx.doi. org/10.1146/annurev.med.57.121304.131337
18. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express FoxP3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004; 172:5986-93; PMID: 15128781
19. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FoxP3(+) conventional T cells. Eur J Immunol 2007; 37:2378-89; PMID:17694575; http://dx.doi.org/10.1002/eji.200737594
20. Janson PC, Winerdal ME, Marits P, Thörn M, Ohlsson R, Winqvist O. FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One 2008; 3:e1612, 2008.
21. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of FoxP3 expression in regulatory T cells by DNA methylation. J Immunol 2009; 182:259-73; PMID:19109157
22. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21:2512- 8; PMID:17713545; http://dx.doi.org/10.1038/sj.leu. 2404913
23. Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X, et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4 + T lymphocytes. J Immunol 2008; 181:2506-12; PMID:18684941
24. Clark RA, Shackelton JB, Watanabe R, Calarese A, Yamanaka K, Campbell JJ, et al. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood 2011; 117:1966-76; PMID: 21148332; http://dx.doi.org/10.1182/blood-2010-05-287664
25. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen AM, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia 2008; 22:2230-9; PMID: 18769452; http://dx.doi.org/10.1038/leu.2008.224
26. Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, et al. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. J Invest Dermatol 2009; 129:2875-85; PMID:19626037; http://dx.doi.org/10.1038/jid. 2009.175
27. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011; 117:6532-41; PMID:21493801; http://dx.doi. org/10.1182/blood-2010-11-317321
28. Schmidl C, Hansmann L, Andreesen R, Edinger M, Hoffmann P, Rehli M. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. Eur J Immunol 2011; 41:1491-8; PMID: 21469109; http://dx.doi.org/10.1002/eji.201041067
29. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011; 12:247-54; PMID:21278738; http://dx.doi.org/10.1038/ni.1995
30. Marzec M, Halasa K, Kasprzycka M, Wysocka M, Liu X, Tobias JW, et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008; 68:1083-91; PMID:18281483; http://dx.doi. org/10.1158/0008-5472.CAN-07-2403
31. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131:1331-8; PMID:21346774; http://dx.doi.org/10.1038/jid.2011.27
32. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19:209-13; PMID:15618960; http://dx.doi.org/10.1038/sj.leu.2403610
33. Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97:1056-62; PMID:11159537; http://dx.doi.org/10.1182/blood.V97.4. 1056
34. Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003; 102:4059-66; PMID:12829591; http:// dx.doi.org/10.1182/ blood-2003-04-1044
35. Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol 2003; 171:4574-81; PMID:14568931
36. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
37. Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF). Am J Dermatopathol (In press).
38. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105:20852-7; PMID:19088198; http://dx.doi.org/10.1073/pnas.0810958105
39. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93:9148-53; PMID:8799169; http://dx.doi.org/10.1073/pnas.93.17.9148
40. Witkiewicz A, Raghunath P, Wasik A, Junkins- Hopkins JM, Jones D, Zhang Q, et al. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol 2007; 38:462-7; PMID:17239936; http://dx.doi.org/10.1016/j.humpath.2006.09.012
41. Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413-24; PMID:21268011; http://dx.doi.org/10.1002/eji.201040979